Also from this source

You just read:

XTL Biopharmaceuticals In-licenses hCDR1, a Phase 2 Clinical Stage Asset for the Treatment of Lupus

News provided by

XTL Biopharmaceuticals Ltd

Jan 08, 2014, 08:00 EST